Type I interferons: History and perspectives as immunotherapeutic agents against cancer

Página do item simplificado
dc.contributor.authorGorgulho, Carolina Mendonça [UNESP]
dc.contributor.authorRomagnoli, Graziela Gorete [UNESP]
dc.contributor.authorKaneno, Ramon
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUNOESTE
dc.contributor.institutionBRA
dc.date.accessioned2023-07-29T13:42:55Z
dc.date.available2023-07-29T13:42:55Z
dc.date.issued2020-09-24
dc.description.abstractInterferons (IFNs) were first described in the context of viral infection as macromolecules capable of interfering with the ability of a viral particle to infect a host cell. Besides viral interference, since their discovery, IFNs have been further implicated in different processes linked to immunity and cancer. The family of IFNs has been divided into three categories according to biological properties and signaling pathways: type I IFNs (consisting of IFN-α and β), type II IFNs (IFN-γ, also known as the immune IFN), and type III IFNs (consisting of IFN-λ). This chapter focuses on type I IFNs, which are closely linked to key processes in cancer, such as malignant transformation, differentiation, tumor cell growth, and death. Within the immune system, type I IFNs communicate with several populations involved in the antitumor immune response, such as NK (natural killer) and dendritic cells, contributing to cancer immunoediting. Type I IFNs are approved for the treatment of a number of cancers, including melanoma, renal cell carcinoma, and Kaposi's sarcoma. However, currently the biggest challenge in the therapeutic use of type I IFNs, as well as other cytokines, is the toxic side effects, which can compromise the efficacy of the treatment and reduce patient's quality of life. In this chapter, we review the biology of type I IFNs along with many therapeutic approaches being currently explored in order to reduce toxicity and fully harness the antitumor potential of type I IFNs.en
dc.description.affiliationDepartment of Pathology Medical School of Botucatu São Paulo State University
dc.description.affiliationDepartment of Health Science Oeste Paulista University UNOESTE
dc.description.affiliationDepartment of Chemical and Biological Sciences Biosciences Institute of Botucatu BRA
dc.description.affiliationUnespDepartment of Pathology Medical School of Botucatu São Paulo State University
dc.format.extent183-197
dc.identifierhttp://dx.doi.org/10.1007/978-3-030-50287-4_11
dc.identifier.citationCancer Immunology: Bench to Bedside Immunotherapy of Cancers, Second Edition, p. 183-197.
dc.identifier.doi10.1007/978-3-030-50287-4_11
dc.identifier.scopus2-s2.0-85148484597
dc.identifier.urihttp://hdl.handle.net/11449/248394
dc.language.isoeng
dc.relation.ispartofCancer Immunology: Bench to Bedside Immunotherapy of Cancers, Second Edition
dc.sourceScopus
dc.subjectCancer immunology
dc.subjectDendritic cells
dc.subjectImmunotherapy
dc.subjectInterferon alpha/beta
dc.subjectNK cells
dc.subjectType I interferons
dc.titleType I interferons: History and perspectives as immunotherapeutic agents against canceren
dc.typeCapítulo de livro

Arquivos

Coleções

Artigos - Patologia - FMB